Profile data is unavailable for this security.
About the company
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
- Revenue in USD (TTM)5.05m
- Net income in USD-46.90m
- Incorporated1989
- Employees60.00
- LocationArmata Pharmaceuticals Inc5005 Mcconnell AveLOS ANGELES 90066United StatesUSA
- Phone+1 (310) 665-2928
- Fax+1 (310) 665-2963
- Websitehttps://www.armatapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benitec Biopharma Inc | 0.00 | -46.30m | 373.38m | 19.00 | -- | 1.99 | -- | -- | -1.11 | -1.11 | 0.00 | 5.47 | 0.00 | -- | -- | 0.00 | -34.33 | -79.73 | -35.10 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 374.03m | 106.00 | -- | 2.37 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 378.15m | 32.00 | -- | 1.46 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 378.56m | 16.00 | -- | 4.50 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 384.05m | 4.00 | -- | 175.01 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -22.76m | 384.53m | 38.00 | -- | 3.60 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 391.74m | 60.00 | -- | -- | -- | 77.51 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 397.48m | 305.00 | -- | 0.6421 | -- | 14.03 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 397.74m | 834.00 | -- | 0.6854 | -- | 2.20 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 403.02m | 104.00 | 20.78 | 5.69 | 19.01 | 3.23 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 410.54m | 34.00 | -- | 3.24 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Absci Corp | 2.82m | -114.60m | 412.02m | 156.00 | -- | 1.95 | -- | 146.37 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Organogenesis Holdings Inc | 465.22m | -13.39m | 412.94m | 869.00 | -- | 1.60 | 86.24 | 0.8876 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 414.02m | 27.00 | -- | 8.02 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
Data as of Mar 02 2026. Currency figures normalised to Armata Pharmaceuticals Inc's reporting currency: US Dollar USD
2.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 305.62k | 0.84% |
| 683 Capital Management LLCas of 31 Dec 2025 | 139.86k | 0.38% |
| Geode Capital Management LLCas of 31 Dec 2025 | 109.89k | 0.30% |
| Edgewood Management LLCas of 31 Dec 2025 | 100.00k | 0.28% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 68.50k | 0.19% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 61.79k | 0.17% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 50.80k | 0.14% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 48.07k | 0.13% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 45.16k | 0.12% |
| Bridgeway Capital Management LLCas of 31 Dec 2025 | 44.68k | 0.12% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
